Igantet

Human Tetanus Immunoglobulin, the active ingredient in Igantet, is an immunoglobulin presented as a sterile injectable solution for intramuscular use. It provides passive immunity to neutralize tetanus toxin and is employed in both prophylaxis and treatment of tetanus in individuals with uncertain vaccination status or confirmed infection.

GNH USA supplies Igantet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and offers reliable global distribution, supporting rapid delivery to emergency and routine care settings.

Igantet, a human tetanus immunoglobulin, provides passive immunity against tetanus toxin.

- Pre‑exposure prophylaxis in individuals with uncertain vaccination status: provides immediate protection pending active immunization. - Post‑exposure prophylaxis after contaminated wound: neutralizes toxin to prevent tetanus development. - Adjunctive therapy in confirmed tetanus cases: supplies antibodies while active vaccine induces long‑term immunity.

Igantet may be associated with adverse reactions typical of human immunoglobulin preparations.

Common Side Effects: - Pain at the injection site: mild to moderate discomfort. - Redness or swelling at the injection site: localized inflammatory response. - Fever: transient elevation of body temperature. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Serum sickness-like reaction: fever, rash, arthralgia occurring days after administration. - Severe hypotension: sudden drop in blood pressure during or after injection. - Urticaria: widespread hives indicating allergic response. - Hemolysis: destruction of red blood cells in rare cases.

When using Igantet, clinicians should observe the following precautions to ensure safe administration.

- Assess vaccination history: verify prior tetanus immunization status before administration. - Screen for hypersensitivity: avoid in patients with known allergy to human immunoglobulins. - Monitor during injection: observe for immediate allergic reactions such as rash or breathing difficulty. - Use aseptic technique: prepare injection site with sterile equipment to prevent infection. - Avoid in IgA‑deficient patients with anti‑IgA antibodies: risk of severe anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igantet can interact with certain medicines and biologics; awareness of these interactions helps manage patient safety.

Major Interactions (Avoid): - Concurrent administration of other human immunoglobulins: may cause immunoglobulin overload and increased viscosity. - Live attenuated vaccines within 3 months: reduced vaccine efficacy due to passive antibodies. - Simultaneous blood product transfusion: may interfere with antibody activity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased risk of bleeding at injection site. - Immunosuppressive agents (e.g., corticosteroids): may diminish the protective effect of administered antibodies. - Active tetanus vaccine given shortly after Igantet: schedule appropriately to avoid interference.